Does B12 deficiency lead to lack of treatment response to conventional antidepressants?

Ms. Kate is Junior Resident is from the Department of Psychiatry, Postgraduate Institute of Medical Education and Research, Chandigarh, India.
Psychiatry 11/2010; 7(11):42-4.
Source: PubMed


We present two cases of treatment-resistant depression that improved with recognition and correction of the underlying medical etiology of vitamin B12 deficiency. Supplementations of vitamin B12 to the same antidepressant regimen that the patient had not responded earlier led to response. Two male subjects who were vegetarians presented with long-standing histories of depression and had not responded to three adequate trials of antidepressants. Upon investigation, the authors found that the subjects had low vitamin B12 levels. Both cases improved with supplementation of vitamin B12. Subjects with depression who do not respond to conventional antidepressants should be evaluated for nutritional factors.

Download full-text


Available from: Natasha Kate, Sep 28, 2014
15 Reads
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Vitamin B12, cyanocobalamin, is implicated in metabolic and neurotrophic functions. Its deficiency is associated with hematological, neurological and psychiatric disorders. Herein we report the case of a patient presenting with refractory depression who improved after the identification and treatment of vitamin B12 deficiency. This report highlights the relevance of considering secondary causes of depression in refractory cases.
    Jornal brasileiro de psiquiatria 12/2010; 60(2):141-143. DOI:10.1590/S0047-20852011000200010
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Ali Akhondpour Manteghi , Roya Samadi , Parisa Samadi Abstract: Introduction:Megaloblastic anemias are group of disorders that usually are caused by deficiency of vitamin B12 or folate. Vitamin B12 deficiency occurs with a wide range of symptoms of hematology، neurology، gastrointestinal or psychiatry. Untreated anemia prevents the appropriate treatment even if the patient be treated properly for psychiatric disorder، will be often having inadequate response or resistance to treatment. Materials and Methods: This paper presents a 33 years old woman who had experienced depression and mood lability and had been under psychiatric treatment with various psychiatric diagnoses such as borderline personality disorder، major depressive disorder and mood disorder NOS. During the six month before admission balance impairment، paresthesia، coldness and pain in lower limbs was gradually added to her symptoms. She was admitted to psychiatric hospital as a result of her suicidal thoughts and function disturbances. Complete blood count and serum B12 and folic acid levels were performed with suspicion to megaloblastic anemia. Following confirmation of diagnosis (low serum B12:90 pg ml) and treatment onset، symptoms disappeared dramatically within a few days. Patient was discharged from psychiatric hospital and in order to determine causes of megaloblastic anemia she was referred to an internist. Conclusion:Mental disorders are prevalent in cobalamin deficiency، so even in the absence of anemia or neurological symptoms of B12 deficiency، probability of megaloblastic anemia should be considered in atypical symptoms or psychiatric disorders، refractory to conventional treatments، fluctuating and uncommon symptoms. Keywords:Depression, Megaloblastic anemia, Vitamin B12
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The definition of dual tryptophan pathways has increased the understanding of the mind-body, body-mind dichotomy. The serotonergic pathway highlights the primary (endogenous) psychiatric disorders. The up-regulation of the kynurenine pathway by physical illnesses can cause neuropathic and immunological disorders1 associated with secondary neuropsychiatric symptoms. Tryptophan and nicotinamide deficiencies fall within the protein energy malnutrition (PEM) spectrum. They can arise if the kynurenine pathway is stressed by primary or secondary inflammatory conditions and the consequent imbalance of available catabolic/anabolic substrates may adversely influence convalescent phase efficiency. The replacement of depleted or reduced NAD+ levels and other cofactors can perhaps improve the clinical management of these disorders. Chronic fatigue syndrome (CFS) and fibromyalgia (FM) appear to meet the criteria of a tryptophan-kynurenine pathway disorder with potential neuroimmunological sequelae. Aspects of some of the putative precipitating factors have been previously outlined.2,3 An analysis of the areas of metabolic dysfunction will focus on future directions for research and management.
    International Journal of Tryptophan Research 07/2013; 6(Suppl 1):39-45. DOI:10.4137/IJTR.S11193
Show more

Similar Publications